drugset / Trial / NCT04432103

Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma

NCT04432103 ↗

Phase 3 Terminated 6 enrolled Centro Medico ABC
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Open label two arms, non randomized Convalescent Plasma treatment to severe and critical pneumonia COVID-19 hospitlaized patients compared to a historical cohort with matched controls.

Timeline

Start
2020-08-08
Primary completion
2021-01-29
Completion
2021-01-29

Outcome

Outcome not reported

Stopped: “There is new evidence that the Convalescent plasma is not useful for severe and critical COVID-19 Pneumonia”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject anti-SARS-CoV-2 convalescent plasma Protein / enzyme biologic — —

Indications